License Agreements - Additional Information (Details) - USD ($)	1 Months Ended							3 Months Ended		6 Months Ended
	May 31, 2024	Dec. 31, 2022	Mar. 31, 2022	Jan. 31, 2021	Apr. 30, 2020	Mar. 31, 2020	Feb. 29, 2020	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
License Agreements [Line Items]
In-process research and development								$ 22,500,000		$ 22,500,000
License Agreement | Novartis Pharma AG
License Agreements [Line Items]
Upfront payment		$ 20,000,000
In-process research and development								0	$ 0	0	$ 0
Stock issued, value		$ 80,000,000
Stock issued and sold		12,307,692
License Agreement | Novartis Pharma AG | Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation		$ 80,000,000
Sales milestone payments obligation		$ 200,000,000
License Agreement | NiKang Therapeutics, Inc.
License Agreements [Line Items]
Upfront payment							$ 5,000,000
Reimbursement of certain initial manufacturing costs							400,000
Payment for US patent application					$ 7,000,000
In-process research and development								0	0	0	0
License Agreement | NiKang Therapeutics, Inc. | First Licensed Product
License Agreements [Line Items]
Payment of development and regulatory milestone obligation				$ 4,000,000
License Agreement | NiKang Therapeutics, Inc. | First Licensed Product | Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation							16,000,000
Commercial milestone payments obligation							157,000,000
License Agreement | NiKang Therapeutics, Inc. | Second Licensed Product
License Agreements [Line Items]
Development and regulatory milestone payments obligation							12,000,000
Commercial milestone payments obligation							$ 151,000,000
License Agreement | Katmai Pharmaceuticals, Inc.
License Agreements [Line Items]
Upfront payment						$ 5,700,000
Payment of development and regulatory milestone obligation			$ 2,000,000
In-process research and development								0	$ 0	0	$ 0
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock
License Agreements [Line Items]
Stock issued, value						$ 2,700,000
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock | IPO
License Agreements [Line Items]
Conversion of convertible preferred stock into common stock						395,555
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-1 Convertible Preferred Stock
License Agreements [Line Items]
Stock issued, value					$ 1,800,000
Stock issued and sold					356,000
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-2 Convertible Preferred Stock
License Agreements [Line Items]
Stock issued, value				$ 900,000
Stock issued and sold				118,666
License Agreement | Katmai Pharmaceuticals, Inc. | Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation						$ 26,000,000
Commercial milestone payments obligation						$ 101,000,000
Joyo License Agreement | Guangzhou Joyo Pharmatech Co., Ltd.
License Agreements [Line Items]
Upfront payment	$ 12,500,000
In-process research and development								12,500,000		12,500,000
Joyo License Agreement | Guangzhou Joyo Pharmatech Co., Ltd. | Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation	51,500,000
Development and regulatory milestone payments obligation if territory expanded	57,500,000
Commercial milestone payments obligation	125,000,000
Joyo License Agreement | Guangzhou Joyo Pharmatech Co., Ltd. | Phase 2 Clinical Trial
License Agreements [Line Items]
Payment for option to expand territory of license on or prior to first dosing of first patient	50,000,000
Payment for option to expand territory of license after first dosing of first patient	150,000,000
Medshine License Agreement | Medshine Discovery Inc.
License Agreements [Line Items]
Upfront payment	10,000,000
In-process research and development								$ 10,000,000		$ 10,000,000
Medshine License Agreement | Medshine Discovery Inc. | Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation	30,000,000
Commercial milestone payments obligation	$ 130,000,000